Tocqueville Asset Management L.P. Purchases New Position in SI-BONE, Inc. (NASDAQ:SIBN)

Tocqueville Asset Management L.P. acquired a new position in SI-BONE, Inc. (NASDAQ:SIBN) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 170,000 shares of the company’s stock, valued at approximately $2,383,000.

Other institutional investors also recently bought and sold shares of the company. FMR LLC grew its position in shares of SI-BONE by 103.6% during the 3rd quarter. FMR LLC now owns 2,354 shares of the company’s stock worth $33,000 after buying an additional 1,198 shares in the last quarter. Mainstream Capital Management LLC purchased a new stake in SI-BONE in the fourth quarter worth about $53,000. R Squared Ltd bought a new position in SI-BONE during the 4th quarter worth about $73,000. Walleye Capital LLC purchased a new position in SI-BONE during the 3rd quarter valued at about $144,000. Finally, Proficio Capital Partners LLC bought a new stake in shares of SI-BONE in the 4th quarter valued at about $155,000. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SIBN has been the topic of a number of recent research reports. Needham & Company LLC increased their price objective on shares of SI-BONE from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Tuesday, February 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 target price on shares of SI-BONE in a research report on Tuesday, February 25th. Finally, Truist Financial reiterated a “buy” rating and issued a $22.00 price target (up from $18.00) on shares of SI-BONE in a report on Tuesday, February 25th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $24.50.

SI-BONE Price Performance

Shares of SIBN opened at $14.79 on Wednesday. The company has a 50 day moving average of $16.57 and a two-hundred day moving average of $14.83. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. SI-BONE, Inc. has a twelve month low of $11.70 and a twelve month high of $19.16. The company has a market cap of $627.88 million, a price-to-earnings ratio of -16.08 and a beta of 1.17.

SI-BONE (NASDAQ:SIBN) last posted its quarterly earnings data on Monday, February 24th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. The firm had revenue of $49.00 million during the quarter, compared to analysts’ expectations of $48.87 million. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. As a group, analysts predict that SI-BONE, Inc. will post -0.78 earnings per share for the current fiscal year.

Insider Activity at SI-BONE

In related news, insider Anthony J. Recupero sold 3,670 shares of SI-BONE stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $13.90, for a total transaction of $51,013.00. Following the completion of the sale, the insider now owns 222,814 shares of the company’s stock, valued at $3,097,114.60. The trade was a 1.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Anshul Maheshwari sold 5,304 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $13.91, for a total transaction of $73,778.64. Following the completion of the transaction, the chief financial officer now owns 189,319 shares in the company, valued at approximately $2,633,427.29. This trade represents a 2.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 9,311 shares of company stock valued at $130,356 in the last three months. 3.90% of the stock is owned by insiders.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.